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1. Introduction 
Adrenal medulla is regarded as a model of neurons 
containing catecholamine (CA), and is the most 
suitable tissue for studying the regulation of CA release 
and synthesis. Recently, some investigations have 
been carried out on these problems using isolated 
adrenal medullary cells [ 141. Such preparations are 
suitable for use in elucidating how stimulation of 
membrane receptors is coupled with release and 
synthesis of CA. We have also isolated bovine adrenal 
medullary cells, which respond to acetylcholine 
(ACh), nicotine or excess K+ (56 mM), by release of 
CA and increased synthesis of CA [5]. 
Here, we examine the effect of cholinergic agents 
and of excess K’ on the level of cyclic GMP (cGMP) 
in the isolated cells and found that the cGMP level 
was increased via stimulation of muscarinic ACh 
receptors. The increase in cGMP level is considered 
in relation to the release of CA from the cells. 
During preparation of this manuscript Schneider 
et al. [6] reported that the level of cGMP could be 
increased by ACh at lower concentrations than that 
required to initiate the release of CA from the isolated 
ceils. 
2. Methods 
Bovine adrenal medullary cells were isolated in 
large quantity by sequential digestion of adrenal 
medullary slices with collagenase as in [S]. The 
isolated cells (“2 X 10e6 cells/ml) were incubated at 
37OC with or without test compounds in Krebs- 
Ringer phosphate (KRP) buffer (pH 7.4) containing 
0.5% bovine serum albumin, in 2 ml final vol. When 
56 mM K+ was used, the Na+ content was decreased 
to keep the tonicity of the KRP buffer constant. 
For determination of cGMP, the reaction was 
stopped by addition of 0.2 ml ice-cold 70% trichIoro- 
acetic acid. cGMP was separated on an ion exchange 
column (AG 50 W X 8, H-type, 200-400 mesh) [7] 
and measured by radioimmunoassay (assay kit). For 
determination of CA release, after incubation, the 
tubes were rapidly chilled in an ice-water bath, then 
centrifuged at 600 X g for 5 min in the cold. CA in 
the cells and medium was extracted with 0.4 N 
perchloric acid and measured fluorimetrically [8]. 
3. Results and discussion 
ACh (3 X 1 Om6) was found to increase the level of 
cGMP -S-fold in isolated bovine adrenal medullary 
cells. As shown in fig.1, increase in the cGMP level was 
observed after incubation with ACh for only 30 s, 
the shortest time examined. The maximum cGMP 
level was observed after incubation for 2 min, and 
then the level decreased rapidly to normal. In the 
presence of 3-isobutyl-l-methyl-xan~ine (IBMX, 
0.3 mM) a phosphodiesterase inhibitor, the maximum 
level of cGMP was observed after 2-5 min incubation, 
then decreased more slowly. 
The increase in cGMP level caused by ACh was 
dependent on the presence of extracellular Ca2+; it 
was abolished by omission of Ca2+ from the medium 
and increased linearly with increase in concentration 
of Ca2* to -2 mM (data not shown). 
296 
Volume 105, number 2 FEBS LETTERS September 1979 
1-+--l- 
o 1 2 3 4 5 15 30 mill 
Fig.1. Time course of the effect of ACh on the level of CCMP 
in isolated bovine adrenal medullary cells. Cells were incubated 
in the presence or absence of 3 X 10m6 M ACh for the 
indicated periods. When the phosphodiesterase inhibitor 
IBMX (0.3 mM) was added, cells were preincubated with 
IBMX for 10 min then ACh was added, and incubations were 
continued for the indicated times. fo- 0) Control; 
(A----A) IBMX (-); (+----- .) IBMX (+). 
Figure 2 shows the dose-response curve for the 
effect of ACh on the cGMP level. Increase in the 
cGMP level was detectable with as low as lob8 M 
ACh, and the maximal response was observed with 
10e6 M ACh. The half-rn~rn~ response was 
obtained at -2 X 10e7 M ACh. It is of interest o 
compare this dose-response curve with that for the 
effect of ACh on the release of CA from the cells. 
Release of CA occurred at >10m6 M ACh, the con- 
centration for the maximal increase in the cGMP 
level, and was maximal at 10V4 M ACh. These 
findings are quite in agreement with [6] and are 
interesting in relation to the possible role of cGMP 
in regulation of CA release. 
Figure 3 shows the effects of cholinergic agents 
and of excess K+ on the cGMP level and release of 
CA from the cells. Increase in the cGMP level caused 
by ACh was inhibited by atropine, a muscarinic 
antagonist, but not by hexamethonium, a nicotinic 
antagonist, indicating that the ACh-induced increase 
in the cGMP level involved an interaction of ACh 
with muscarinic ACh receptors rather than nicotinic 
ACh receptors. On the other hand, the release of 
CA from the cells caused by ACh was inhibited by 
hexamethonium. Atropine also inhibited the release 
of CA, suggesting that atropine interacts with 
nicotinic AC% receptors, since it is well known 
that the release of CA from bovine adrenal medulla 
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Fig.2 Dose-response curves for ACh-Induced increase in 
cGMP level and AC&induced CA release. Cells were pre- 
incubated for 10 min with IBMX (0.3 mM) then ACh was 
added, and incubations were continued for 5 min (for deter- 
mination of cGMP) or 1 min (for determination of CA 
release). Maximal response: WMP = 15 pmol/mg protein; 
CA release = 1 l-12% of the total intracellular CA content. 
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Fig.3. Effects of choline@ agents and excess K‘ on the 
level of cCMP and release of CA. Cells were preincubated for 
10 min with or without cholinergic antagonist (3 x lo-* M) 
in the presence of IBMX (0.3 mM), then ACh (10e4 M) or an 
other cholinergic agonist (lo-’ M) was added, and incuba- 
tions were continued for 5 min (for cGMP) or 1 min (for CA 
release). To test the effect of excess K+, the second 
incubation was carried out in medium containing 56 mM 
K+. 
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Fig.4. Dose-response curve for nicotine-induced CA release 
and effect of muscarine on it. Cells were preincubated for 
10 min with or without muscarine (10m5 M) in the presence 
of IBMX (0.3 mM), then various concentrations of nicotine 
were added and the incubations were continued for 1 min. 
Maximal CA release represented 10% of the total intracellular 
CA content. (e- l ) Nicotine; (o---o) nicotine + 
muscarine. 
is mediated predominantly by nicotinic ACh 
receptors [9]. 
The mediation of muscarinic ACh receptors in the 
ACh-induced increase in the cGMP level was also 
indicated from results with other cholinergic agonists. 
The muscarinic agonists muscarine and methacholine 
caused 4-S-fold increase in the cGMP level, but they 
did not cause release of CA. On the contrary, nicotine 
or excess K’, which caused release of CA, did not 
significantly alter the level of cGMP. 
It does not appear from these results that there is a 
parallel relation between increase in the cGMP level 
in the cells and release of CA from the cells. 
Next, we examined the possibility that the increase 
in cGMP via stimulation of muscarinic ACh receptors 
may inhibit the release of CA mediated by stimula- 
tion of nicotinic ACh receptors. Figure 4 shows the 
dose-response curve for nicotine-induced CA release 
from the isolated cells. The effective concentration 
range of nicotine for release of CA was found to be 
lower than that of ACh. However, the release of CA 
caused by various concentrations of nicotine was not 
affected by the presence of muscarine, which increased 
the level of cGMP in the cells. 
The physiological role of cGMP in bovine adrenal 
medullary cells is unknown. The role of cGMP in 
regulation of CA synthesis is now under investigation. 
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